The introduction of advanced therapy medicinal products (ATMPs) to the global pharma
market has been revolutionizing the pharmaceutical industry and has opened new routes for …

Thalassemia and sickle cell disease (SCD) are the most common monogenic diseases in
the world and represent a growing global health burden. Management is limited by a paucity …

Blood and marrow transplantation (BMT) is rarely available in many low-to middle-income
countries (LMICs). In 2012, Civil Service Hospital, a government hospital in Kathmandu …

Developing an Allogeneic Hematopoietic Progenitor Cell Transplant Service in a Resource-Limited
Country: Challenges and Outcomes - PMC Back to Top Skip to main content NIH NLM Logo …

The scope and application of hematopoietic stem cell transplantation are increasing. With
advancement in science and close cooperation of health centers, HSCT units are coming up …

Haematopoietic stem cell transplantation (HSCT) is a much‐needed service in Tanzania, to
provide curative therapy for sickle cell disease (SCD), aplastic anaemia and haematological …

There is paucity of data on outcomes of MSD‐HSCT in children with relapsed or high‐risk
AML from developing countries, which have unique challenges including adverse host …

As cellular therapies gradually become the mainstay of treatment for several nonmalignant
diseases, there appears to be varied accessibility to these therapies globally. Despite …

Background The role of splenectomy prior to hematopoietic stem cell transplantation (HSCT)
is controversial. Only few studies compared the outcomes of splenectomized and …

Introduction. Due to the significant resources involved in creating HSCT programs there is a
significant disparity in the availability of this treatment modality between the developed and …